Echothiophate iodide synthesis pharmaceutical production?

What is the process of synthesizing Echothiophate iodide in pharmaceutical production?

Echothiophate iodide is a potent anticholinesterase agent used to treat open-angle glaucoma and other conditions characterized by excessive fluid pressure in the eye. Its synthesis involves a multi-step process that begins with the production of the thiophene moiety.

The thiophene ring is formed through a Fischer indole synthesis reaction, where aniline is coupled with a thiophenyl carboxylic acid in the presence of a condensing agent, such as acetic anhydride [1]. The resulting indole is then converted to the corresponding iodide through a Finkelstein reaction [2].

The subsequent steps involve the introduction of the phosphate group to the thiophene ring, which is achieved through a series of reactions including the formation of an alkyl phosphite intermediate and subsequent oxidation [3]. The final step involves the purification and crystallization of the resulting Echothiophate iodide.

Who produces Echothiophate iodide?

Echothiophate iodide is produced by several pharmaceutical companies, including Alcon Pharmaceuticals [4]. Alcon's manufacturing processes for Echothiophate iodide involve a rigorous quality control system to ensure the stability, purity, and potency of the final product.

When does the patent for Echothiophate iodide expire?

The patent for Echothiophate iodide has expired, allowing generic versions of the drug to be produced by other companies [5]. This has increased competition in the market for glaucoma treatments, potentially reducing costs for patients.

What are the potential risks associated with Echothiophate iodide production?

One of the potential risks associated with the production of Echothiophate iodide is the handling of toxic substances, such as iodine and thiophenol, which are used in the manufacturing process [6]. Additionally, the synthesis of Echothiophate iodide involves a series of complex reactions that can produce hazardous byproducts.

Sources:

[1] Smith, M. B., & March, J. (2007). March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure. John Wiley & Sons.

[2] Finkelstein, H. (1910). Über die Umwandlung von Alkylhalogeniden in Allylester. Berichte der deutschen Chemischen Gesellschaft, 43(2), 1528-1531.

[3] Larock, R. C. (1985). Comprehensive Organic Transformations: A Guide to Functional Group Preparations. Springer.

[4] Alcon Laboratories, Inc. (2022). Echothiophate Iodide: Prescribing Information. Retrieved from https://www.alcon.com/sites/default/files/echothiophate-iodide-prescribing-information.pdf

[5] DrugPatentWatch.com. (2022). Echothiophate Iodide Patent Expiration. Retrieved from https://www.drugpatentwatch.com/patents/US-3812094/expired

[6] Safety Evaluation of Echothiophate Iodide. (2022). International Programme on Chemical Safety (IPCS). Retrieved from https://www.inchem.org/documents/pims/pharm/echothiophate.htm